Invasive Fungal Infection
Conditions
Keywords
Adult, allo-Stem Cell Transplantation, Cord Blood
Brief summary
Infections due to post transplant immune deficiency are a major problem following allogeneic stem cell transplantation (Allo-SCT), particularly in patients receiving cord blood transplant (CB). Duration of neutropenia is one of the most important risk factor for invasive fungal infection (IFI). In this setting, Micafungin has been approved for antifungal prophylaxis for patients undergoing Allo-SCT. In a randomized, double-blind, comparative, phase III trial, the overall efficacy of micafungin was superior to that of fluconazole as antifungal prophylaxis during the neutropenic phase after Allo-SCT. However, very few patients in this study received a CB transplant. This is phase IIb, prospective, open-label, non-comparative study to assess the safety of micafungin when use in prevention of IFI in neutropenic patients receiving allo-SCT using CB as source of stem cells.
Interventions
DRUGMicafungin
All patients meeting selection criteria will receive micafungin IV. Prophylaxis will start within 48 hours of the beginning of the transplant-related conditioning regimen until 5 days after recovery from neutropenia (ANC ≥ 500/µl), or occurrence of an IFI, or up to 42 days, or withdrawal for any reason (e.g. patient's or investigator's decision, development of intolerance, death), whichever come first
Sponsors
Nantes University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Adult patients receiving allo-Stem Cell Transplantation using Cord Blood as source of stem cells (cf conditioning regimen recommendation). * Sex male or female * Age between 18 and 65 years at the time of signing the informed consent form. * Diagnosis of an hematologic disease for who a allograft decision has been taken * not having a (HLA)-matched related or unrelated donor within two month after complete remission achievement * Able to understand and voluntarily sign an informed consent form. * Subjects affiliated with an appropriate social security system * Male, female without childbearing potential or negative urine pregnancy test at the screening visit prior to beginning the treatment. Women of childbearing potential must be following adequate contraceptive measures. Men must agree to use an acceptable method of contraception (for themselves or female partners) for the duration of the study * Each subject will weigh 40 kg or more
Exclusion criteria
* Any suspected or documented invasive fungal infection at study entry or at any time prior to study entry * Use of any systemic antifungal therapy within 72 hours prior to study entry * Known history of allergy, hypersensitivity or intolerance to echinocandin agents * Patient with any medical, psychological or social condition, which in the opinion of the investigator could increase the risk to the patient, or decrease the chance of obtaining satisfactory data to achieve the objectives of this study. * Participation in a study testing a new drug or a new conditioning * HIV, HBV or HCV positive * Pregnant or breast feeding females. * Subject protected by law.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety | 50 days | Safety assessed by the incidence and type of adverse events (AE) occurring during the course of prophylaxis treatment, AE related to study drug, AE leading to study drug discontinuation, and evolution of vital signs and biological parameters. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Invasive Fungal Infection | 50 days | Incidence of Invasive Fungal Infection (IFI) at the end of prophylaxis period and at the end of the 4-week follow-up period |
| Incidence of fever of unknown origin | 50 days | Incidence of fever of unknown origin requiring empirical antifungal treatment during prophylaxis period |
| Survival rate | 50 days | Survival rate and incidence of mortality related to IFI from the start of prophylaxis until the end of the 4-week follow-up period. |
Countries
France
Outcome results
None listed